Expertise in
10
conditions

Dr. Leslie K. Ballas

Radiation Oncology
Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, 
West Hollywood, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
10
conditions
Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, 
West Hollywood, CA 

Overview

Leslie Ballas is a Radiation Oncologist practicing medicine in West Hollywood, California.

Dr. Ballas is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Muscle Invasive Bladder Cancer, Prostate Cancer, Familial Prostate Cancer, Bladder Reconstruction, and Prostatectomy.

She is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 11 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in CA

Hospital Affiliations

Cedars-Sinai Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Cedars-Sinai Radiation Oncology-Los Angeles
8720 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma
Phase II Multi-Institutional Study of Low-Dose (2Gy) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: June 05, 2026
Intervention Type: Other, Radiation
Study Phase: Not Applicable
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Radiation
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
View 9 Less Clinical Trials

88 Total Publications

GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor Therapy.
GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor Therapy.
Journal: medRxiv : the preprint server for health sciences
Published: June 12, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Mitchell R. Kamrava
Radiation Oncology
Expertise in
21
conditions
Dr. Mitchell R. Kamrava
Radiation Oncology
Referral may be required

Cedars-Sinai Radiation Oncology-Los Angeles

8720 Beverly Blvd, 
West Hollywood, CA 
 (0.1 miles away)
310-423-4208
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mitchell Kamrava is a Radiation Oncologist practicing medicine in West Hollywood, California. Dr. Kamrava is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Vaginal Cancer, Prostate Cancer, Prostatectomy, and Vitrectomy.

Expertise in
35
conditions
Dr. Tania B. Kaprealian
Radiation Oncology
Expertise in
35
conditions
Dr. Tania B. Kaprealian
Radiation Oncology
Referral may be required

Office

200 Medical Plz, 
Los Angeles, CA 
 (3.8 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tania Kaprealian is a Radiation Oncologist practicing medicine in Los Angeles, California. Dr. Kaprealian is highly rated in 35 conditions, according to our data. Her clinical expertise encompasses Meningioma, Radiation Induced Meningioma, Metastatic Brain Tumor, Schwannoma, and Thalamotomy.

Expertise in
32
conditions
Dr. Arya Amini
Radiation Oncology
Expertise in
32
conditions
Dr. Arya Amini
Radiation Oncology
Referral may be required

City Of Hope National Medical Center Radiology

1500 Duarte Rd, 
Duarte, CA 
 (23.7 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arya Amini is a Radiation Oncologist practicing medicine in Duarte, California. Dr. Amini is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Glossectomy, and Penectomy.

Frequently Asked Questions about Dr. Leslie K. Ballas

How do I make an appointment with Dr. Leslie K. Ballas?

You can book an appointment with Dr. Leslie K. Ballas by calling their office at 310-423-4208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leslie K. Ballas a top-rated expert for Muscle Invasive Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leslie K. Ballas is classified as an Elite expert for Muscle Invasive Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leslie K. Ballas specialize in?

While Dr. Leslie K. Ballas is a Radiation Oncology, they have specific expertise in Muscle Invasive Bladder Cancer, Prostate Cancer, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Leslie K. Ballas participate in research or clinical trials?

Yes. Dr. Leslie K. Ballas has published 88 articles and abstracts on conditions like Muscle Invasive Bladder Cancer. You can view a list of Dr. Leslie K. Ballas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Leslie K. Ballas accept my insurance?

Dr. Leslie K. Ballas accepts most major insurance plans, including Alignment Health Plan and Anthem BCBS. We recommend calling the office directly at 310-423-4208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ballas's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile